Stock comparison
Novartis AG is 107.8x more valuable than Immunome Inc. by market capitalization ($295.04 B vs $2.74 B). Compare market value, revenue, profit, margins, filings, and source pages in one place.
Quick answer
NVS is larger
Novartis AG is 107.8x more valuable than Immunome Inc. by market capitalization ($295.04 B vs $2.74 B).
Market value leader
NVS
Novartis AG is 107.8x more valuable than Immunome Inc. by market capitalization ($295.04 B vs $2.74 B).
| Metric | IMNM | NVS |
|---|---|---|
| Market cap | $2.74 B | $295.04 B |
| US-listed rank | #1911 | #46 |
| Revenue (latest FY) | $6.94M | - |
| Net income (latest FY) | -$212.39M | - |
| Net margin | -3060.0% | - |
| P/E (trailing FY) | - | - |
| SEC filings | 413 | 981 |
Jump from this comparison into the underlying pages for market value, annual fundamentals, and company filing history.
Market cap uses refreshed market data. Revenue, net income, margins, and trailing fiscal-year P/E use annual company facts from filings. If a metric is missing, the source data did not have a clean recent annual value for that company.
Novartis AG is 107.8x more valuable than Immunome Inc. by market capitalization ($295.04 B vs $2.74 B).
Full pages: Immunome Inc. and Novartis AG, or browse the full rankings.